NKTR (Nektar Therapeutics Inc) Net Profit

NKTR (Nektar Therapeutics Inc.) - company brandmark

Nektar Therapeutics (NKTR) possesses a powerful business moat driven by exclusive patents in immuno-oncology and strict oversight from US regulators. Its status as an experienced market player and the trust of its counterparties are based on years of practice in refining therapeutic molecules. The company's price chart on GURU.Markets, where the profit indicator is -0.16, is supplemented by data on the implementation of automated systems for high-precision analysis of biologics.

NKTR (Nektar Therapeutics) Net Profit history from 07/04/2022 to 11/01/2026

Analytical breakdowns and data insights for company Nektar Therapeutics Inc. (NKTR)

- price and consensus price forecast:
Stock Quotes Nektar Corp|NKTR - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Nektar Corp|NKTR - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Nektar Therapeutics|NKTR - Book Capitalization|Market Capitalization to Book Value nektar.com|NKTR - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Nektar Therapeutics|NKTR - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Nektar Therapeutics Inc|NKTR - Company Total Debt|Debts to Book Capitalization Nektar Corp|NKTR - Company Long-Term Debt|Company Short-Term Indebtedness Nektar Therapeutics|Immediate Liquidity nektar.com
- net income and valuation multiples indicators:
NKTR - Company Net Income
Summary company analysis:Nektar Therapeutics
Core merchandise of Nektar

Nektar Therapeutics (NKTR) maintains a powerful patent portfolio in polymer synthesis that creates long-term technological barriers for competitors. An analysis of the company's income and expense balance allows for an assessment of the monetization efficiency of these developments. This indicator captures the final financial result after deducting all operating expenses from revenue. Identifying a sustainable profit price corridor helps investors avoid purchasing the asset at a local peak. Such securities belong to the high-risk biotechnology sector.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN - Company Net Income|PHAR (Pharming Corp) - Company Profit|UPB: Net Profit|Company Net Income zenasbio.com (ZBIO)|Company Net Income Immunome|Net Profit Gossamer Bio Inc|Net Income KALV (KalVista Pharmaceuticals Inc)|Profit After Payment of Taxes SEPN|Net Profit PVLA (Pieris Pharmaceuticals)|Net Profit savarapharma.com SVRA|RIGL - Company Net Income|Final Profit ANAB (AnaptysBio Inc)|ATXS (Astria Pharma) - Net Income|enGene Corp - Final Profit|Net Income RAPT|JBIO (Aerovate) - Profit After Payment of Taxes|Net Profit ACRS|KYTX (Kyverna Therapeutics Inc.) - Final Profit|Net Profit TLSA (Tiziana Life Sciences PLC)|Cabaletta Bio Inc (CABA) - Company Net Income|VTYX - Company Net Income|Final Profit THTX (theratech.com)|AVTX: Net Profit|Eledon Pharmaceuticals Inc. (ELDN) - Net Profit|Company Net Income Agenus Inc|Climb Bio, Inc - Profit After Tax|Net Profit ZURA|ATYR - Company Net Income|Adagene Inc. - Net Income|Net Profit ImageneBio IMA|STTK: Net Income|Equillium, Inc. - Profit After Payment of Taxes|CNTB: Net Profit|IMUX - Net Financial Result|ATRA (Atara Biotherapeutics, Inc.) - Net Profit|Net Income InflaRx GmbH (IFRX)|Company Net Income X4 Pharma (XFOR)|Net Financial Result adicetbio.com|Company Net Income Celularity CELU|INMB: Company Profit|BRNS - Company Net Income|KZR - Net Profit|SABS (SAB Biotherapeutics, Inc) - Net Income|AKTX: Profit After Payment of Taxes|Company Net Income Enlivex Therapeutics Ltd|QTTB: Final Profit|Company Net Income GeoVax (GOVX)|EDSA: Profit After Tax|Net Profit IBIO (iBio Corp)|Final Profit CARM|XTL Biopharmaceuticals - Net Profit|BOLT - Net Profit|hcwbiologics.com (HCWB) - Company Net Income|Aptevo Therapeutics Inc. - Final Profit|Company Net Income AIM ImmunoTech|Net Income Aditxt Corp (ADTX)|Net Profit GRI|Net Profit xortx.com (XRTX)|Vyome Holdings - Net Income|Final Profit REVB|Indaptus - Net Profit|Net Financial Result BiondVax Pharmaceuticals SCNI|calcimedica.com (CALI) - Company Net Income|Net Income Affimed N.V.|Company Net Income Allakos Inc|Net Income HOOKIPA (HOOK)|Net Income IGMS (IGM Biosciences, Inc.)|Net Profit iTeos Pharma (ITOS)|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP: Company Profit|Third Harmonic Bio, Inc. - Net Profit